ResMed Analyst Maintains Overweight Rating
This is a news story, published by Yahoo Finance, that relates primarily to David Bailey news.
David Bailey news
For more David Bailey news, you can click here:
more David Bailey newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
moderate sleep apnea. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest obstructive sleep apnea news, Hypopnea Index reduction news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mean ApneaTipRanks
•Health
Health
Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed

80% Informative
Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $ 286 price target.
Apnimed provided topline results as part of its Phase 3 trial for AD109 , focused on the treatment of obstructive sleep apnea.
Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% .
VR Score
72
Informative language
66
Neutral language
71
Article tone
formal
Language
English
Language complexity
60
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
13
Source diversity
2
Affiliate links
no affiliate links